Iran begins first human trial of locally made virus vaccine

Iran has struggled to stem the worst virus outbreak in the region, which has infected over 1.2 million people

Vials of Iranian domestic coronavirus disease (COVID-19) vaccine candidate are seen during human testing in Tehran, Iran December 29, 2020. Organization of the Execution of Imam Khomeini's Order/WANA (West Asia News Agency) via REUTERS ATTENTION EDITORS - THIS IMAGE HAS BEEN SUPPLIED BY A THIRD PARTY.  THIS PICTURE WAS PROCESSED BY REUTERS TO ENHANCE QUALITY. AN UNPROCESSED VERSION HAS BEEN PROVIDED SEPARATELY.

The first study of the safety and effectiveness of a coronavirus vaccine in Iran began on Tuesday, state TV reported.

Dozens of people were due to receive the domestically developed shot even as details about its production remained slim.

The vaccine is produced by Shifa Pharmed, part of a state-owned pharmaceutical conglomerate known as Barekat. It is the first in the country to reach human trials.

The company’s website describes it as being involved in the large-scale production of antibiotics and penicillin. There are no details about its coronavirus research, results of animal trials or previous vaccine development since its founding in 1995.

Iran has struggled to stem the worst virus outbreak in the region, which has infected over 1.2 million people and killed nearly 55,000.

The study, a Phase 1 clinical trial, will enrol a total of 56 volunteers to receive two shots , according to Hamed Hosseini, a clinical trial manager.

Results are to be announced roughly a month after the second shot.

Three people received the first injections on Tuesday in a ceremony at a Tehran hotel attended by the country’s health minister. State TV announced that none of the injections had so far caused any “fevers” or “bodily shocks”.

“I am happy that the scientific process went ahead in a proper way,” said Tayebeh Mokhber, daughter of the Setad Foundation chairman, who was the first to get jabbed. “I hope the conclusion will be health for our people.”


Coronavirus around the world


The Setad Foundation, controlled by the office of Iran’s supreme leader, oversees the Barekat conglomerate.

The treatment, dubbed Coviran, is a so-called inactivated vaccine, meaning it is made of a coronavirus that’s been weakened or killed by chemicals, similar to how polio immunisations are made. Leading Western vaccines, like the shot made by Pfizer and its German partner BioNTech, use newer, less-proven technology to target the coronavirus’ spike protein using RNA.

Iranian authorities expect the vaccine to hit the market by late spring 2021, an extremely aggressive timeline. Before this year’s fast-tracked development of coronavirus vaccines, the usual methods of testing a vaccine for safety and efficacy with mass trials could take up to a decade.

With government-funded research into viral proteins and genetics accelerating the development of vaccines worldwide, countries have approved vaccines for emergency use and launched inoculation programmes at record-breaking speed.

American drug makers Pfizer and Moderna received endorsements after reporting their vaccines were more than 90 per cent effective at protecting against the coronavirus in large, advanced clinical trials. China and Russia approved their vaccines for emergency use while still in late-stage testing. Their early interim data, although promising, lacks clarity and raises questions about vaccine efficacy.

Iran has not elaborated on its regulatory approval process or plans for more advanced trials.

President Hassan Rouhani has said Iran is co-operating with a “foreign country” to produce another vaccine expected to run in tests in human volunteers in February, without offering further details.

The government has touted Iran’s domestic vaccine research, repeatedly alleging that tough American sanctions undermine efforts to purchase foreign-made vaccines and launch mass inoculation campaigns like those under way in the U.S. and Europe. While U.S. sanctions do have specific carve-outs for medicine and humanitarian aid to Iran, international banks and financial institutions hesitate in dealing with Iranian transactions for fear of being fined or locked out of the American market.

Still, Iran retains routes to imported vaccines, including through Covax, an international programme designed to distribute coronavirus vaccines to participating countries around the world.

Iran’s energy minister, Reza Ardakanian, told state news agency IRNA on Tuesday during a visit to Baghdad that Iran will pay for the Covax vaccines from some $6 billion that Iraq owes Iran for gas imports over the years.

On Monday, Iran said it expects a group of US-based benefactors to ship thousands of Pfizer coronavirus vaccines in the coming weeks.